Our lead, SUN 1334 H, is a novel antiallergic molecule that is currently in phase II clinical trials in the US. This is a selective histamine H1 receptor antagonist used for the therapy of allergic disorders such as seasonal and perennial allergic rhinitis, urticaria, etc. In preclinical studies, SUN-1334H was found to have high specificity for histamine H1 receptors. Preclinical studies have also shown SUN 1334H to have a clean pharmacodynamic, safety and toxicological profile, including desirable characteristics such as fast onset of action, and lack of sedation. Clinically, this could eventually confer low side effect potential for the molecule, besides good efficacy in patients afflicted with allergies.